Sales of its obesity therapies may be accelerating, but Novo Nordisk is showing no signs of pushing the brake pedal on investments in the category.Amongst its interim results statement, the Danish drugmaker revealed that it has agreed to buy Canada’s Inversago Pharma, a specialist in metabolic disorders that focuses on the development of peripherally acting […]
